Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

HHS develops national plan to prevent Healthcare-Associated Infections

Independent evaluators have found that measurable progress in reducing the rates of some targeted HAIs has been achieved under the umbrella of a national plan to prevent HAIs that was developed by the U.S. Department of Health and Human Services (HHS).

24 Jan 2014

Research may lead to potential treatment for deadly bacterial infections

Collaboration between the National University of Singapore (NUS) and The Hebrew University of Jerusalem (HUJ) on inflammation research may lead to a potential treatment for deadly bacterial infections

20 Jan 2014

TaiGen, R-Pharm sign exclusive agreement to develop and commercialize nemonoxacin

TaiGen Biotechnology Company, Limited today announced that they have signed an exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn) in the Russian Federation, Turkey and other members of the Commonwealth Independent States.

15 Jan 2014

Hussey Copper launches new line of home improvement products that fight deadly bacteria

Hussey Copper, a leader in copper manufacturing, with support from Lynn Tilton and Patriarch Partners, today launches a new line of home improvement products that fight deadly bacteria known to lurk on surfaces.

10 Jan 2014

IBM and OhioHealth collaborate to aid in prevention of infections in hospitals

OhioHealth and IBM today announced a collaboration to aid in the prevention of infections using a first-of-a-kind network of wireless sensors and real-time Big Data analytics that measure hand-washing practices.

10 Jan 2014

Study finds significant decline of MRSA infections in VA long-term care facilities

Four years after implementing a national initiative to reduce methicillin-resistant Staphylococcus aureus rates in Veterans Affairs long-term care facilities, MRSA infections have declined significantly, according to a study in the January issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology.

7 Jan 2014

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.

30 Dec 2013

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

TaiGen Biotechnology Company, Limited today announced that the U.S. Food and Drug Administration has granted nemonoxacin (Taigexyn) Qualified Infectious Disease Product and Fast Track designations for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

23 Dec 2013

Researchers develop new vaccine that protects against lethal pneumonia caused by staph bacteria

University of Iowa researchers have developed a new vaccine that protects against lethal pneumonia caused by Staphylococcus aureus (staph) bacteria, including drug-resistant strains like MRSA.

23 Dec 2013

MicuRx announces initiation of global clinical development program for MRX-I compound

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the initiation of a global clinical development program for its lead compound MRX-I, a novel oxazolidinone antibiotic for treatment of Gram-positive infections including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.

20 Dec 2013

Arizona scientists investigate intriguing effects of spaceflight on microbial pathogens

At Arizona State University's Biodesign Institute, Cheryl Nickerson and her team have been investigating the intriguing effects of spaceflight on microbial pathogens.

17 Dec 2013

Scientists reveal how MRSA strain rapidly rises to prominence

Scientists believe they have an explanation for how the most common strain of methicillin-resistant Staphylococcus aureus rapidly rose to prominence. Research published in mBio-, the online open-access journal of the American Society for Microbiology, suggests that the strain recently acquired a number of genes from common skin bacteria that allow it to grow and thrive on the skin where other strains of MRSA cannot.

17 Dec 2013

Study: Blue light proves to have powerful bacteria-killing ability

Blue light has proven to have powerful bacteria-killing ability in the laboratory. The potent antibacterial effects of irradiation using light in the blue spectra have now also been demonstrated in human and animal tissues. A series of groundbreaking articles that provide compelling evidence of this effect are published in Photomedicine and Laser Surgery, a peer-reviewed journal published by Mary Ann Liebert, Inc., publishers.

16 Dec 2013

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA (methicillin-resistant Staphylococcus aureus) could serve as a safe and effective vaccine against this toxin. This "nanosponge vaccine" enabled the immune systems of mice to block the adverse effects of the alpha-haemolysin toxin from MRSA-both within the bloodstream and on the skin. Nanoengineers from the University of California, San Diego described the safety and efficacy of this nanosponge vaccine in the December 1 issue of Nature Nanotechnology.

2 Dec 2013

Inhibitor compounds could form basis of new treatments for such diseases as MRSA, anthrax

Inhibitor compounds developed by UC Irvine structural biologists and Northwestern University chemists have been shown to bolster the ability of antibiotics to treat deadly bacterial diseases such as MRSA and anthrax.

27 Nov 2013

Researchers identify key immune cells that turn body's defenders against invading golden staph

When golden staph enters our skin it can identify the key immune cells and 'nuke' our body's immune response.

26 Nov 2013

Staphylococcus Aureus Bacteria anticipates and turns immune defenses against the host

Around 20 percent of all humans are persistently colonized with Staphylococcus aureus bacteria, a leading cause of skin infections and one of the major sources of hospital-acquired infections, including the antibiotic-resistant strain MRSA.

20 Nov 2013

Rapid DNA biochip tests for screening disease-causing bacteria

Patients affected by a bacterial infection can usually be treated with an antibiotic. But sometimes a resistant bacterial strain is causing the infection. In a hospital setting, doctors ideally want to know if they are dealing with such bacteria and which drugs they should choose. But if the doctor runs a test it can take days to get a result. Now, a European project is paving the way for much more rapid tests using DNA biochips. The aim is to rapidly screen disease-causing bacteria using a microarray to spot which resistant genes are present in bacteria.

20 Nov 2013

Friendly microbes in the guts of healthy children have numerous antibiotic resistance genes

Friendly microbes in the intestinal tracts (guts) of healthy American children have numerous antibiotic resistance genes, according to results of a pilot study by scientists at Washington University School of Medicine in St. Louis.

14 Nov 2013

Groundbreaking study reveals novel approach to treat, eliminate MRSA infection

Recent work from University Distinguished Professor of Biology Kim Lewis promises to overcome one of the leading public health threats of our time. In a groundbreaking study published Wednesday in the journal Nature, Lewis' team presents a novel approach to treat and eliminate methicillin resistant staphylococcus aureus, or MRSA, a potent bacterium whose resistance to antibiotics has kept it one step ahead of researchers.